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Abstract: Dopamine is derived from an amino acid, phenylalanine, which must be obtained through
the diet. Dopamine, known primarily to be a neurotransmitter involved in almost any higher
executive action, acts through five types of G-protein-coupled receptors. Dopamine has been stud-
ied extensively for its neuronal handling, synaptic actions, and in relation to Parkinson’s disease.
However, dopamine receptors can be found extra-synaptically and, in addition, they are not only
expressed in neurons, but in many types of mammalian cells, inside and outside the central nervous
system (CNS). Recent studies show a dopamine link between the gut and the CNS; the mechanisms
are unknown, but they probably require cells to act as mediators and the involvement of the im-
mune system. In fact, dopamine receptors are expressed in almost any cell of the immune system
where dopamine regulates various processes, such as antigen presentation, T-cell activation, and
inflammation. This likely immune cell-mediated linkage opens up a new perspective for the use of
dopamine-related drugs, i.e., agonist–antagonist–allosteric modulators of dopamine receptors, in a
variety of diseases.
Keywords: microbiota; intestinal flora; Parkinson’s disease; immune system; drug development;
receptor heteromers; G protein-coupled receptors; L-DOPA; inflammation; T-cell activation
1. Introduction
Mammalian endogenous monoamines are very interesting compounds. They act as
neurotransmitters and as regulatory molecules that participate in keeping homeostasis,
but that may become part of the problem in some diseases. An example is adrenaline/
noradrenaline, which are neurotransmitters of sympathetic neurons but which, in addition,
are secreted by the adrenal gland to maintain homeostasis. In tumors of the adrenal
gland, overproduction of these monoamines leads to many of the serious symptoms
of the patients. Dopamine (DA) is more known as a neurotransmitter, although it also
acts as a compound that helps in maintaining homeostasis. However, a difference with
adrenaline/noradrenaline is that DA seems to act more in the paracrine mode than in an
endocrine-type fashion.
Monoamines (adrenaline, noradrenaline, DA, etc.) were first detected in the brain.
The first detection of a compound that was likely DA was in 1951 in the brain of different
animals (humans included) [1]. Similar studies but addressing regional distribution failed
to detect DA in areas of low noradrenaline content (e.g., the caudate putamen) [2]. A few
years later, the compound, which was neither noradrenaline nor adrenaline, was isolated
and identified as DA by paper chromatography [3,4]. At that moment, the main question
was the physiological role of DA. A very important piece of information came from the
discovery that L-DOPA, which is the precursor of DA (Figure 1), was facilitating waking
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up after hexobarbital anesthesia; the authors of the study postulated that DA was the
active compound whose precursor was L-DOPA [5]. Research in the late 1950s was key in
demonstrating that DA had specific functions in and out of the brain, and that L-DOPA
was a precursor that upon administration to animals could be converted into DA [6,7].
Figure 1. Dopamine synthesis and degradation pathways. ASC, ascorbic acid; COMT, catechol-
o-methyltransferase; DA βH, dopamine β-hydroxylase; DOPAC, 3,4-dihydroxyphenylacetic acid;
DOPA DEC, L-DOPA decarboxylase; L-DOPA, levo-dopa; L-Phe, L-phenylalanine; L-Tyr, L-tyrosine;
MAO, monoamine oxidase; PH, phenylalanine hydroxylase; TH, tyrosine hydroxylase.
A key discovery was the link between dopamine deficiency and Parkinson’s disease
(PD). Several laboratories participated, some to discover that the cause of PD was in the
brain structures related to the striatum, and others showed that it was a lack of dopamine
in the substantia nigra which, in turn, led to the depletion of DA in the striatum. Soon after
these early discoveries, L-DOPA was proposed as a medication to combat the symptoms of
PD (see Ref. [8] for a detailed account of the discovery of DA and of DA deficiency in the
Parkinsonian brain) [9,10]. Studies with animal models of PD have suggested that the motor
disturbances are due to a disbalance in the so-called direct and indirect striatal pathways,
in which neurons projecting to the globus pallidus and substantia nigra pars reticulata have
two different types of dopamine receptors (D1 or D2; five DA receptor types have been
discovered; see below). This view has been recently challenged by immunochemical-based
assays in non-human primates showing that striatal neurons may express the two receptor
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types [11], and by single-axon tracing studies (also in non-human primates), indicating
evidence against a dual striatofugal system [12].
Dopamine is now arising as one of the most relevant neurotransmitters, as it seemingly
participates directly or indirectly in almost any physiological function occurring in the
central nervous system (CNS). This review presents information about dopamine that
has mainly been obtained from enzymatic studies, and about the link with PD, without
forgetting the actions that DA exerts in the periphery. The review also highlights the
cell-based communication that links the gut and the CNS.
2. Dopamine, Dopamine Receptors and Catechol-Related Enzymes
DA, or 4-(2-aminoethyl)-1,2-benzenediol, is one of the main neurotransmitters in the
mammalian nervous system. In the central nervous system, it is produced and released
by the so-called dopaminergic neurons, which are found in different brain areas but are
especially abundant in the substantia nigra. Dopaminergic neurons of the substantia nigra
pars compacta project to the striatum, where specific receptors are activated and the signal
is transmitted by projection neurons and further circuitry to the pallidus, the thalamus,
and the substantia nigra pars reticulata. DA participates in almost any centrally controlled
event, from motor control to cognition.
Overall, DA acts via two well-described mechanisms, namely, wiring and volume
transmission. Wiring transmission participates in releasing DA to the synaptic cleft, where
it acts on postsynaptic DA receptors. Volume transmission occurs when extracellular DA
arrives to neurons other than those postsynaptically located; i.e., by diffusion, DA reaches
receptors in other neurons (or glial cells) that are not in direct contact with the cell that has
released the neurotransmitter [13–16]. This means that the brain contains a certain degree
of dopaminergic tone resulting from the DA that, released to the extracellular medium,
activates extrasynaptic receptors in different cells across the brain.
So far, five DA receptors have been described (D1, D2, D3, D4 and D5), which belong to
the superfamily of G protein-coupled receptors (GPCRs). For many years it was assumed
that DA’s role in the brain consisted of producing variations in intraneuronal cAMP
levels, and in the activation/inactivation of protein kinase, which in turn regulates the
activity of a protein that is considered key in dopaminergic neurotransmission, DA- and
cAMP-regulated phosphoprotein of 32 kDa molecular weight (DARPP32). The cognate
protein of D1 and D5 receptors is Gs, whose engagement activates adenylate cyclase, thus
leading to increases in cytosolic cAMP levels. Instead, the cognate protein of the D2, D3
and D5 receptors is Gi, whose engagement inactivates adenylate cyclase, thus leading to
decreases in cytosolic cAMP levels [17]. Gs or Gi coupling may occur in cells other than
neurons because DA receptors are found in many cell types (even in the periphery), thus
substantiating the interpretation that DA is more than a neurotransmitter. As shown below,
there are splice variants of dopamine receptors; some of them are “natural”, i.e., occurring
in all individuals, and some vary from individual to individual and may be associated with
impulsive behaviors or with the risk of addiction. Splice variants are mainly described for
the D2 and the D4 receptors; importantly, other gene polymorphisms described for all five
receptors, including single nucleotide polymorphism, may be associated with a variety of
addictions (drugs, alcohol, etc.) and obesity [18–25]; other non-dopamine-receptor-related
factors also influence addictive behaviors.
3. Features of DA Receptors That Are Important in Dopaminergic Transmission in
Both Health and Disease
For decades it was assumed that the DA link to calcium-mediated actions was indirect.
However, the laboratory of Susan George provided evidence that the D1–D2 receptor
assemblies couple to Gq/11 instead of coupling to Gs or Gi [26,27]. Gq coupling allows
calcium mobilization, this being a direct link between DA and actions mediated by the ion.
The controversy as to whether D1–D2 receptor interactions do not occur in primates was
solved by the demonstration that there are a significant percentage of neurons expressing
D1–D2 receptor complexes in the Macaca fascicularis monkey model [11]. A physiolog-
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ical role of D1–D2 receptor heteromers was demonstrated in the healthy brain, and a
pathophysiological one in models of addiction [11,28–30]. In addition, the same labora-
tory has reported that expression differences depending on the sex affect anxiety- and
depression-like neuropsychiatric diseases [31].
The variety of effects in the healthy brain and the therapeutic potential of targeting
DA receptors in diseases of the nervous system is sustained by the myriad possibilities
derived from the occurrence of complexes formed by DA receptors, or by DA receptors
and other cell surface receptors. DA’s action in a given cell will depend on the DA
receptors expressed on the plasma membrane and on the expression of complexes in which
these receptors participate. Indeed, each receptor–receptor heteromer conveys a different
signaling when activated by DA, i.e., each receptor heteromer has its own physiological
role and pharmacological properties [32–34]. An example that is relevant for Parkinson’s
disease is the occurrence of striatal neurons expressing D1 and adenosine A1 receptors [35],
or D2 and adenosine A2A receptors [36]. The antagonism between the dopaminergic
transmission and purinergic regulation of neurotransmitter release is, in part, due to the
occurrence of these heteromers [37–40].
Other homotropic heteromers that have been so far reported include D1–D3 [41,42],
D2–D3 [43], D2–D5 [28] and D2–D4 [44]. Apart from the A1–D1 and the A2A–D2, other
heterotropic receptor heteromers include the D1–histamine H3 [45], the D2–histamine
H3 [46], the D4–adrenergic [47], etc.; for a complete list of DA receptor-containing com-
plexes, see http://www.gpcr-hetnet.com/ [48]. As an example of the physiological role of
DA-containing heteromers, those involving some adrenergic receptors are involved in the
circadian regulation of melatonin production by the pineal gland [48].
Despite the fact that there are few examples of isoforms in GPCRs, the mRNAs
for the D2 and D4 receptors may suffer differential splicing, thus giving rise to various
isoforms. The most studied is the D2 short and the D2, which differ in the size of the
third intracellular loop [49]. Interestingly, the D2 short may be expressed presynaptically
to regulate neurotransmitter release, thus acting as an autoreceptor [50,51]. The circa 20
variants of the D4 receptor are due to a hypervariable region of the D4 gene; they come
from 27 haplotypes [52,53] and one of them, the D4.7, is associated with attention-deficit
hyperactivity disorder [54]. The structural particularities of the different heteromers, for
instance the interacting interfaces, underlie differential signaling [55–57]. In the case of the
D2 short isoform, it so happens that it may interact with some of the D4 receptor variants
but not with the D4.7 isoform [58]. Whether this lack of homotropic DA receptor–receptor
interaction has an impact on the pathophysiology of attention-deficit hyperactivity disorder
is, at present, unknown.
4. Dopamine, L-DOPA and Parkinson’s Disease
Both imbalances in dopamine neurotransmission and alterations of brain circuits
where dopamine is a key factor are involved in a variety of neurological and neuropsychi-
atric diseases, from alcohol/drug addiction to schizophrenia [18–25,59–62]. In fact, typical
antipsychotics act “almost exclusively on the dopamine system” [63]. A review taking into
account all those diseases is out of the scope of the present review, which will focus on the
main dopamine-associated disease, namely, Parkinson’s disease (PD).
Details of DA synthesis are found in Figure 1. In the human, DA synthesis requires
an essential amino acid, phenylalanine, which is the precursor of another relevant amino
acid, tyrosine, that is the precursor of several bioactive molecules. Two enzymes are
required for DA synthesis: L-tyrosine hydroxylase, which is a used as a marker of DA-
producing cells/neurons, and L-3,4 dihydroxyphenylalanine (L-DOPA) decarboxylase.
In “dopaminergic” cells, DA is the final product that can be re-used or degraded; however,
in cells containing dopamine β-hydroxylase, e.g., cells in the adrenal gland, it is converted
into noradrenaline. It has been considered that phenylalanine is essential because it would
be quite “expensive” to synthesize it in neurons. Evolution has allowed mammals to obtain
phenylalanine from nutrients for the easy procurement of tyrosine and its derivatives (DA,
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thyroxine, adrenaline, tyramine, etc.). This selective advantage has allowed us to save
energy and synthetic enzymes. However, the hydroxylation of tyrosine to lead to L-DOPA
requires reducing power, meaning that sustained DA production may lead to oxidative
stress. To minimize the synthesis of new DA molecules, neurons have specific uptake
mechanisms to incorporate interstitial DA and reuse it.
Parkinson’s disease (PD), resulting from the death of dopaminergic neurons of the
substantia nigra, is characterized by motor symptoms, including tremors at rest and
difficulty in performing movements. Consistent with the key role of DA in reward circuits,
PD associates with impulsive control disorders. Some centers report that up to 40% of
patients have impulsive tendencies, with hypersexuality being the most common, and men
being most at risk (see Ref. [64] for review).
An efficacious drug still used today was suggested decades ago by the seminal work
of Hornykiewicz and colleagues. After discovering that the cause of motor symptoms
was a lack of DA in certain areas of the brain and noticing that DA is unable to cross the
blood–brain barrier, they thought of using L-DOPA, i.e., its precursor. L-DOPA readily
crosses the blood–brain barrier and is converted into DA in the brain. Fluctuations in the
blood/brain levels of the drug and the need for a chronic treatment may lead to some side
effects, mainly dyskinesia [65,66].
5. Dopamine Derivatives in Neurological and Neuropsychiatric Diseases
The route for DA degradation consists of two enzymatic steps catalyzed by monoamine
oxidase and catechol-O-methyl transferase (COMT), which lead to homovanillic acid (IU-
PAC name: 2-(4-hydroxy-3-methoxyphenyl)acetic acid), a compound identifiable in the
urine of healthy individuals (Figure 1). Obviously, the level in the urine decreases in
untreated Parkinsonian patients, while it increases in patients receiving L-DOPA therapy.
Homovanillic acid in the cerebrospinal fluid (CSF) is a surrogate marker for the catabolism
of DA in the central nervous system [67]. The relevance of DA in the circuits involved in
almost any higher function may be deduced from alterations in the levels of homovanillic
acid in the CSF of patients with neurological diseases. An example is provided by tests
in the CSF of 1388 children who were prescribed a lumbar puncture due to neurological
clinical manifestations. The majority of patients had conditions that were not related to
inheritable diseases related to DA. Among them, 696 had a clinical history that allowed
stratification into the following categories, among others: epilepsy/epileptic encephalopa-
thy (n = 206), dysmorphic traits/genetic syndromes (n = 69), motor disturbances (n = 65),
hemorrhagic/ischemic injuries (n = 45) and mitochondrial disorders (n = 47). The level of
the compound was significantly altered in the group of hemorrhagic or hypoxic/ischemic
injuries. In addition, in patients with definitive diagnosis high HVA levels were seldom
found, while low levels were mainly detected in infectious diseases of the CNS and in
perinatal stroke [68]. In summary, measuring homovanillic acid in the CSF may be comple-
mentary but not essential for the diagnosis of neurological alterations [67,69].
In relatively mild conditions, DA may be spontaneously oxidized using molecular
oxygen to produce DA quinones and free radical products. This possibility has attracted
attention as the non-enzymatic degradation of DA leads to aminochrome, the precursor
of the pigment that gives the particular dark color to the substantia nigra, neuromelanin.
Several years ago, the oxidation of DA was linked to an excess of aminochrome and
oxidative stress that could alter mitochondrial function and even produce autophagy in
dopaminergic neurons (see Ref. [70] for review). A recent review has also addressed this
issue [71].
The enzymes involved in the production and the degradation of DA (Figure 1) are
very important in maintaining appropriate catecholamine levels and homeostatic condi-
tions. Drugs that alter the activity of COMT, monoamine oxidase (MAO) or dopamine
β-hydroxylase, may affect dopaminergic neurotransmission and any other DA-mediated
physiological effects. However, the inhibition of COMT or MAO-B at adequate dosages
may be beneficial for neuroprotection in PD [72,73]. The imbalance of systems that de-
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pend on DA may also occur following alterations in the expression of those enzymes, or
polymorphisms in their respective genes [74,75].
6. Dopamine in the Gastrointestinal Tract
The notion of a gut–brain link is gaining momentum due to much evidence regarding
the relevance of the composition of the gut microbiota to staying healthy and/or affecting
the development or course of a disease. The communication starts by the regulation of the
microbiota composition and intestinal function by molecules produced by either microbiota
or gut cells. However, the long-distance regulations are mediated by cells of the immune
system (see Refs. [76–78] for review). Although it is not completely canonical because the
endocrine system involves the blood as a mediator of hormonal action, the concept of
“microbial endocrinology” has been coined to delve into the symbiotic mechanisms that
are established between our cells and the microbes that accompany us in our body [79].
As an example of the gut–brain link, there is cumulative evidence of the role of
gut microbiota in the development of Parkinson’s disease. Although the underlying
mechanisms are not known (see Ref. [80] for a review), it is reasonable to assume that the
DA in the gut is key to a variety of physiological processes that may directly or indirectly
impact on neurotransmission and neuronal fate in the CNS.
The amount of DA in the periphery is much higher than that in the CNS. More than
50 years ago, the release of DA by the rabbit ileum, likely coming from sympathetic nerve
terminals, was demonstrated [81]. Apart from being produced by sympathetic neurons, DA
in the periphery may be produced by a variety of cells. More than 50 years ago, the “staining
characteristics” of so-called “dopamine cells” of the duodenal mucosa of cow or pig were
reported [82]. Previously, a method for identifying monoamines in cells was reported
by Falck [83]. DA in the gastrointestinal tract is surely produced by the phenylalanine
coming from food digestion. The extra amino acid that is not processed in the intestinal
cells is distributed, mainly through the blood, to all the organs of the mammalian body.
In other words, not all phenylalanine coming from food digestion reaches the blood stream.
On the one hand, microorganisms in the gut may both synthesize (using phenylalanine) or
degrade neurotransmitters, DA included [84]. On the other hand, cells of the intestine or
nerves in the intestine may accumulate and/or release DA. An example would be Paneth
cells, whose cytoplasm contains aggregates of DA and 1-3,4-dihydroxyphenylalanine [85].
These are specialized cells, which are monoamine-secreting epithelial cells of the intestine
located in the crypts of Lieberkühn. Paneth cells are involved in controlling the composition
of the intestinal flora [86,87] and, remarkably, these cells together with enterocytes are in
the front line of defense, thus having an intimate relationship with cells of the immune
system [88,89].
A detailed description of all the possibilities of cells involved in phenylalanine and
DA processing is out of the scope of the present review. However, it is worth assuming
that DA locally produced is impacting cells of the gastrointestinal tract, and cells in Peyer’s
patches and mesenteric lymph nodes (Figure 2). Non-neuronal cells surely respond to
DA, but further research is needed in order to know how to take advantage of gut DA
and DA-rich gastrointestinal cells to combat PD and inflammatory bowel diseases [90].
Immune cells, which express different DA receptor types, play a key role (see next section).
A prominent role of polymorphisms of the DRD2 gene, which codes for the D2 receptor,
has been associated with the risk and the course of inflammatory bowel disease and the
efficacy of the treatment; the authors of the study suggested that the receptor might be a
target for Crohn’s patients refractory to the medication [91].
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Figure 2. Dopamine link between gut and inflammation in the periphery and in the CNS. Cells in the
intestine and also gut microbiota cells produce DA, which on one hand influences the composition of
the gut microbiota and on the other hand binds to the dopamine receptors located in the surrounding
cells, including immune cells. (A) In healthy conditions, there is homeostasis of the gut immune
system. (B) In diseases affecting the gut, e.g., autoimmune diseases such as inflammatory bowel
disease, immune cells (DCs, TLs, BLs, etc.) get primed. Macrophages infiltrate from the intestinal
lumen trough the damaged epithelium. These primed immune cells produce local inflammation, but
also reach the blood and may permeate the blood–brain barrier, reaching the brain and boosting CNS
inflammation. BL, B lymphocyte; DC, dendritic cell; DA, dopamine; DR, dopamine receptor; TL,
T lymphocyte.
7. Dopamine, Immune Cells, Inflammation, Autoimmunity and Parkinson’s Disease
Being produced by neurons, or not, DA acts in a wide variety of cells that express DA
receptors. Generally speaking, DA is not an endocrine hormone, i.e., it does not travel by
blood to reach cells in different places in the mammalian body. DA is more a molecule that
acts locally; analogous to synaptic action, the compound may act in different set ups where
cells are exchanging information. Therefore, for DA to act in the gut and have an impact
in the CNS (and other systems), intermediate cells are needed. One of the best examples
of the local action of DA occurs at the so-called immunological synapse where dendritic
cells interact with lymphocytes. Additionally, DA is present in lymph nodes, and not only
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in those of the gastrointestinal tract. Although the role of another “neurotransmitter”,
glutamate, has been more studied in the immunology research field [92], DA plays a key
role in the germ center, where B and T lymphocytes interact. A subpopulation of T helper
cells releases DA that “accelerates productive synapses in germinal centers” [93].
DA acting on T-cells may contribute to neurodegeneration in PD. On the one hand,
the expression of the mRNA transcripts of D3 receptors is altered in blood lymphocytes
from patients [94]. On the other hand, the deletion of the D3 receptor gene or the phar-
macological blockade using receptor antagonists in rodent models of PD protect against
neuroinflammation and dopaminergic denervation [95,96]. It is tempting to speculate
that DA occupies a central place in the gastrointestinal manifestations of PD patients,
also constituting an important piece in the gut–brain communication puzzle occurring in
PD [97–100]. Although DA acting on D3 receptors is noxious in PD models, the deletion of
the receptor leads (in animal models) to chronic depression and anxiety [101].
Via the regulation of cAMP levels and mitogen-activated protein kinase (MAPK) path-
way activation, D3 but also D5 receptors regulate T lymphocyte activation and contribute
to the immune response in a variety of diseases [102]. For instance, D3 receptor-mediated
actions in CD4+ cells favor Th1/Th17-mediated immunity, thus favoring the inflammatory
potential of the lymphocytes [103]. The activation of D5 receptors in myeloid antigen-
presenting cells facilitates the development of an experimental model of autoimmune
disease of the nervous system (encephalitis) [104]. Overall, DA plays an important role
in the immune system, regulating the functionality of dendritic cells and lymphocytes
and, in addition, there is evidence of its important role in the development of autoimmune
diseases [105,106]. The often-found detrimental action exerted by DA acting on lympho-
cytes opens up therapeutic opportunities. Thus, the inhibition of DA receptor-mediated
actions may be beneficial in autoimmune disorders. In addition, it has been proven in an
experimental model that the blockade of D3 receptor-mediated signaling in dendritic cells
favors T-cell-mediated anti-tumor activity [107].
8. Future Perspectives of DA as Neurotransmitter
DA is associated with more diseases than Parkinson’s, and exerts actions that go
beyond the substantia nigra and the striatum. Dopamine receptors are in the reward
circuits in the brain, and are related, for instance, to plastic changes occurring in drug
addiction. As above-mentioned, DA receptors are extrasynaptically located and participate
in, among other things, brain remodeling/plasticity. Accordingly, future research must
address (i) DA receptor (including heteromers) distribution in different areas of the brain
in both health and disease, and (ii) the circuitry associated with executive actions (both in
health and disease).
Knowledge of the reasons why gambling behavior is more widespread in Parkinsonian
men than in Parkinsonian women is lacking. This is an example of what is needed to know
and can be figured out by ad hoc research using animal models or in the human brain (e.g.,
by in vivo positron emission tomography or by immunochemical methods on post mortem
samples). Addressing this topic can not only serve to help better manage the disease, but
can also provide clues as to what may be different in the human brain according to gender:
are the sex hormones that give this differential trait in the circuits related to PD? This is one
of the many interesting questions that arise when considering DA as a neurotransmitter of
the CNS in its broad sense: both in wiring and in volume neurotransmission.
9. Future Perspectives of DA as Regulatory Molecule
The quite recently discovered link that, via dopamine, is established between the gut
and the CNS is very attractive in terms of understanding both how our body works and the
pathophysiological features of some diseases. In fact, our body is constituted by our cells,
but also by exogenous cells, such as those constituting our microbiota. What is the DA
production by microbiota in a healthy gut? Does this DA contribute to that keep pathogens
under control by impacting DA receptors in the immune cells within the gastrointestinal
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tract? Or, otherwise, does the excess or defectiveness of DA in the intestine disrupt such
homeostatic control?
When PD appears and there is evidence of a “dopamine link” between the gut and
the CNS, are events in the gut key for the development of the disease? One conservative
hypothesis would be that PD starts in the brain, and that the gut–brain link may serve
to impact on the denervation rate. Depending on the content of the microbiota and the
status of the immune system components in the gut, primed immune cells (Figure 2) may
reach the brain via infiltrating lymphocytes to boost neuroinflammation and the death of
dopaminergic cells in the substantia nigra. The hypothesis may be wrong, but addressing
it with creative research approaches will surely help to better understand how different
systems interact in both healthy and pathological situations.
There are several questions that can be raised in this exciting field of long-distance
interactions between different organs, with the participation of exogenous cells and having
DA as a mediator.
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